Nurix Therapeutics Inc
NRIX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.65B
Close$
Share Statistics
| Market cap | $2.65 Billion |
|---|---|
| Enterprise Value | $2.65 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.05 |
| Beta | 1.8 |
| Outstanding Shares | 111,084,423 |
Return
| Return on Equity | -84.78% |
|---|---|
| Return on Assets | -63.74% |
| Return on Invested Capital | -74.85% |
Valuation & Multiples
| P/E Ratio | -7.4 |
|---|---|
| PEG | -6.98 |
| Price to Sales | - |
| Price to Book Ratio | 9.06 |
| Enterprise Value to Revenue | 72.17 |
| Enterprise Value to EBIT | -7.65 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 9, 2026
EPS Estimate
$-0.72
Average shareholder expectationRevenue Estimate
$15.29 M
Average shareholder expectationNext Earnings Call
Expected Date
October 8, 2026
EPS Estimate
$-0.56
Average shareholder expectationRevenue Estimate
$22.53 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 5.75% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 18.36%▼ 87.96% |
|---|---|
| Total Invested | $490.30M▼ 72.97% |
| Investors Holding | 65▼ 132.00% |
ESG Score
No data
About Nurix Therapeutics Inc
2,020 employeesNurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other ch...